Source: HAVN Life Sciences
  • HAVN Life Sciences Inc. (HAVN) has launched its second line of natural health products – the Brain Evolve Series
  • The four new SKUs are Brain Evolve AM, Brain Evolve PM Flavoured, Brain Evolve PM, Unflavoured and Brain Evolve Anti-Aging
  • HAVN Life’s Brain Evolve Series includes a range of natural ingredients that support trauma recovery and counteract the effects of brain degeneration
  • Each formulation is designed to support inflammation reduction and restorative sleep, and promote increased energy and memory
  • HAVN Life Sciences Inc. (HAVN) remained unchanged at $0.065 at 9.00 ET

HAVN Life Sciences (HAVN) has launched its second line of natural health products – the Brain Evolve Series.

The four new SKUs (stock-keeping units) – Brain Evolve AM, Brain Evolve PM Flavoured, Brain Evolve PM, Unflavoured and Brain Evolve Anti-Aging – are now available for purchase on yourHAVNlife.com, shipping across Canada and the U.S.

The full line will also be available on Amazon and at GNC locations across Canada in late spring.

HAVN Life’s Brain Evolve Series includes a range of natural ingredients that are known to support trauma recovery and counteract the effects of brain degeneration.

Each formulation is designed to support inflammation reduction and restorative sleep, and promote increased energy and memory.

Created and patented by HAVN Life’s Director of Education, Matthew Bennett, the Brain Evolve Series formulations were designed to address symptoms of concussion and traumatic brain injury, as well as support cognitive health.

Scientific research has shown that there is currently limited effective pharmaceutical treatment for traumatic injury, and has pointed to a larger picture of what occurs in the body following brain injury—most notably the changes in nutrient levels within the brain and body.

“With the launch of the Brain Evolve Series, HAVN Life demonstrates its commitment to helping communities thrive, bringing high-quality and science-based nutraceuticals to market over the past 12 months,” stated Tim Moore, CEO of HAVN Life.

“With multiple distribution and supply partnerships in place in Canada, the U.S. and Australia, our goal is to consolidate our retail presence globally, as a go-to purveyor of the best available products that support brain health and cognitive function,” he added.

HAVN Life Sciences Inc. is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients, the development of natural health products, and innovative therapies to support brain health and cognitive function.

HAVN Life Sciences Inc. (HAVN) remained unchanged at $0.065 at 8.00 ET.

More From The Market Online

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

Buzz on the Bullboards: Looking for volatility-proof stocks?

Investors saw developments in Canadian and U.S. stock markets, with attention on decisions made by central banks and moves in key sectors.